PT85073B - Processo para aumentar a proliferacao de celulas b mediante a utilizacao de ligandos - Google Patents

Processo para aumentar a proliferacao de celulas b mediante a utilizacao de ligandos Download PDF

Info

Publication number
PT85073B
PT85073B PT85073A PT8507387A PT85073B PT 85073 B PT85073 B PT 85073B PT 85073 A PT85073 A PT 85073A PT 8507387 A PT8507387 A PT 8507387A PT 85073 B PT85073 B PT 85073B
Authority
PT
Portugal
Prior art keywords
cells
cell
proliferation
fab
bcgf
Prior art date
Application number
PT85073A
Other languages
English (en)
Portuguese (pt)
Other versions
PT85073A (en
Inventor
Jeffrey A Ladbetter
Edward A Clark
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen filed Critical Oncogen
Publication of PT85073A publication Critical patent/PT85073A/pt
Publication of PT85073B publication Critical patent/PT85073B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT85073A 1986-06-13 1987-06-12 Processo para aumentar a proliferacao de celulas b mediante a utilizacao de ligandos PT85073B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87388486A 1986-06-13 1986-06-13

Publications (2)

Publication Number Publication Date
PT85073A PT85073A (en) 1987-07-01
PT85073B true PT85073B (pt) 1990-07-31

Family

ID=25362524

Family Applications (1)

Application Number Title Priority Date Filing Date
PT85073A PT85073B (pt) 1986-06-13 1987-06-12 Processo para aumentar a proliferacao de celulas b mediante a utilizacao de ligandos

Country Status (22)

Country Link
JP (1) JPH0762040B2 (de)
KR (1) KR910004100B1 (de)
AT (1) AT398437B (de)
AU (1) AU617087B2 (de)
BE (1) BE1000587A4 (de)
CA (1) CA1338781C (de)
CH (1) CH676600A5 (de)
CY (1) CY1681A (de)
DE (1) DE3719398C2 (de)
DK (1) DK173940B1 (de)
FR (1) FR2607136B1 (de)
GB (1) GB2191494B (de)
GR (1) GR870930B (de)
HK (1) HK10293A (de)
IE (1) IE60486B1 (de)
IL (1) IL82841A (de)
IT (1) IT1208649B (de)
LU (1) LU86919A1 (de)
NL (1) NL195022C (de)
PT (1) PT85073B (de)
SE (1) SE504675C2 (de)
SG (1) SG118992G (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443427A (en) * 1982-06-21 1984-04-17 Sidney Farber Cancer Institute, Inc. Monoclonal antibody
EP0117705A3 (de) * 1983-02-24 1985-09-25 The Regents Of The University Of California Monocyten und Blastzellen spezifischer monoklonaler Antikörper
FR2547731A1 (fr) * 1983-06-27 1984-12-28 Centre Nat Rech Scient Immunotoxine antitumorale, preparations pharmaceutiques la contenant et son utilisation in vitro
US4585742A (en) * 1983-12-14 1986-04-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibody with specificity to human small cell carcinoma and use thereof

Also Published As

Publication number Publication date
ATA151387A (de) 1994-04-15
IL82841A0 (en) 1987-12-20
IE60486B1 (en) 1994-07-27
DE3719398C2 (de) 1996-03-28
NL195022C (nl) 2003-06-18
GB2191494B (en) 1990-08-22
BE1000587A4 (fr) 1989-02-14
HK10293A (en) 1993-02-19
SE8702463D0 (sv) 1987-06-12
JPH0762040B2 (ja) 1995-07-05
FR2607136A1 (fr) 1988-05-27
AU617087B2 (en) 1991-11-21
GR870930B (en) 1987-12-16
IE871563L (en) 1987-12-13
IT1208649B (it) 1989-07-10
GB8713650D0 (en) 1987-07-15
JPS6480299A (en) 1989-03-27
DK173940B1 (da) 2002-03-04
DE3719398A1 (de) 1988-01-28
IL82841A (en) 1992-11-15
GB2191494A (en) 1987-12-16
LU86919A1 (fr) 1989-03-08
CH676600A5 (de) 1991-02-15
CY1681A (en) 1993-10-10
DK302287D0 (da) 1987-06-12
NL8701371A (nl) 1988-01-04
AU7421487A (en) 1987-12-17
KR910004100B1 (ko) 1991-06-22
SE8702463L (sv) 1987-12-14
IT8720899A0 (it) 1987-06-12
SG118992G (en) 1993-01-29
FR2607136B1 (fr) 1989-09-15
AT398437B (de) 1994-12-27
CA1338781C (en) 1996-12-10
SE504675C2 (sv) 1997-04-07
DK302287A (da) 1987-12-14
PT85073A (en) 1987-07-01
KR880000582A (ko) 1988-03-28

Similar Documents

Publication Publication Date Title
US5182368A (en) Ligands and methods for augmenting B-cell proliferation
Zanders et al. Tolerance of T-cell clones is associated with membrane antigen changes
US5786456A (en) Bp 50-specific antibodies and fragments thereof
Clark et al. Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50.
Hara et al. Human T cell activation. I. Monocyte-independent activation and proliferation induced by anti-T3 monoclonal antibodies in the presence of tumor promoter 12-o-tetradecanoyl phorbol-13 acetate.
Ledbetter et al. Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells.
Ledbetter et al. Antibodies to common leukocyte antigen p220 influence human T cell proliferation by modifying IL 2 receptor expression.
Noelle et al. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells.
Inaba et al. Direct activation of CD8+ cytotoxic T lymphocytes by dendritic cells.
JP4148537B2 (ja) Ｃｄ４０ｃｒレセプター及びそれに対するリガンド
Indiveri et al. Ia-like antigens on human T lymphocytes: relationship to other surface markers, role in mixed lymphocyte reactions, and structural profile.
Tan et al. Enhancement of natural killer activity by an antibody to CD44.
WO2010135242A1 (en) Combinations of immunostimulatory agents, oncolytic virus, and additional anticancer therapy
Clark et al. Activation of human B cell proliferation through surface Bp35 (CD20) polypeptides or immunoglobulin receptors.
US7476385B2 (en) Methods of inhibiting IgE responses to thymus-dependent antigens with the anti-gp39 antibody MR1
Horowitz et al. Expression and regulation of Ly-6 differentiation antigens by murine osteoblasts
Bekoff et al. Activation requirements for normal T cells: accessory cell-dependent and-independent stimulation by anti-receptor antibodies.
Huet et al. Role in T-cell activation for HLA class I molecules from accessory cells: further distinction between activation signals delivered to T cells via CD2 and CD3 molecules.
Haagen et al. The efficacy of CD3 x CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: the effect of repeated addition of BsAb and interleukin-2
PT85073B (pt) Processo para aumentar a proliferacao de celulas b mediante a utilizacao de ligandos
Tanaka et al. Inhibitory effect of anti-class II antibody on the spontaneous activation of B cells in patients with systemic lupus erythematosus. Analysis with IL-1 production and IL-1 receptor expression.
Leanderson et al. Effects of μ‐specific antibodies on B cell growth and maturation
Butcher et al. Flow cytometric studies of IL-4-stimulated expression of the CD25 antigen by quiescent human B lymphocyte subpopulations.
HARA et al. Human T cell activation
van Endert et al. Monoclonal antibodies to idiotype inhibit in vitro growth of human B-cell lymphomas